Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to dafabet online casino games® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder
– National direct-to-patient program allows patients and caregivers to obtain dafabet online casino games extended-release tablet prescriptions from digital pharmacy –
MONMOUTH JUNCTION, NJ, October 30, 2023 – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ dafabet online casino games® dafabet online casino games (amphetamine) extended-release tablets.
Together, Tris Pharma and Perigon launched a direct-to-patient program, DYANAVEL Delivered, that allows patients and caregivers to seamlessly access dafabet online casino games extended-release tablets through Perigon’s digital pharmacy, enhance their medication management, and receive reimbursement assistance and support to help navigate their treatment journey while reducing administrative burden for both patients and providers. The program is available across the United States, enabling nationwide access to dafabet online casino games extended-release tablets. Patients and physicians wishing to access the DYANAVEL Delivered program can learn more at www.dafabet online casino gamescom/delivered.
“This partnership underscores our continued commitment to ensuring patients have access to the medications they need to treat their ADHD symptoms,” said Ketan Mehta, founder and CEO at Tris Pharma. “In an environment where shortages have been significant and widespread for more than a year, Tris Pharma is among the relatively few companies that have managed to not only maintain but increase supply of our ADHD medications without interruption. Our program with Perigon builds on this success by offering patients a more convenient way to consistently obtain access to their dafabet online casino games extended-release tablet prescription.”
Since the November 2021 approval of dafabet online casino games extended-release tablets, Tris Pharma has seen a consistent increase in prescription volume and taken steps to manage manufacturing volume to ensure that the company is able to consistently meet and exceed demand. The DYANAVEL Delivered program is designed to help eliminate bottlenecks by delivering dafabet online casino games extended-release tablets directly to patients and caregivers.
“We’re incredibly excited to partner with Tris Pharma on this program, because we believe it has the potential to enhance quality of care and reduce prescription access challenges for ADHD dafabet online casino games during a particularly critical time,” said Ted Mills, CEO at Perigon Pharmacy 360. “Additionally, this partnership will provide important insights about the impact of innovative technology and advanced healthcare solutions on real-world patient outcomes.”
dafabet online casino games extended-release tablets are approved for the treatment of ADHD in patients aged 6 years and older. This medication is developed using Tris Pharma’s proprietary Liquidafabet online casino games® technology to create a non-degrading diffusion coating that offers a consistent, controlled release of medication over time.
dafabet online casino games is a federally controlled substance (CII) because it contains amphetamine that can be a target for people who abuse prescription medicines or street drugs. Keep dafabet online casino games in a safe place to protect it from theft. Never give your dafabet online casino games to anyone else because it may cause death or harm them. Selling or giving away dafabet online casino games may harm others and is against the law. See additional important safety information below.
About dafabet online casino games
dafabet online casino games is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain and neurological disorders, including addiction and diseases of the central nervous system. Tris is an established commercial organization with a robust portfolio of best-in-class ADHD products and a promising pipeline of differentiated, near-term drug candidates. More information is available at www.trispharma.com and on LinkedIn @TrisPharma.
About Perigon Pharmacy 360
Perigon Pharmacy 360 is an independent specialty pharmacy that is working to provide care and support to those in need. Perigon serves dafabet online casino games in all 50 states, plus D.C., and are focused on helping improve the patient experience through access to medications, caregiver awareness, provider engagement, and clinical support of our Care Teams. Perigon also utilizes the proprietary Medesto platform, together with the specialty and traditional care pharmacy, to create a Precision Digital Pharmacy model with the goal of improving medication adherence and, clinical outcomes. Perigon Pharmacy 360 is redefining the manner in which dafabet online casino games interact with the critical role of the Pharmacist. For more information, please visit www.perigonpharmacy.org
INDICATION
dafabet online casino games is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and older.
IMPORTANT SAFETY INFORMATION
WARNING: ABUSE, MISUSE, AND ADDICTION
dafabet online casino games has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dafabet online casino games, can result in overdose and death. Before prescribing dafabet online casino games, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
- dafabet online casino games is contraindicated:
- In patients known to be hypersensitive to amphetamine, or other components of dafabet online casino games. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported with other amphetamines.
- in dafabet online casino games taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of increased risk of hypertensive crisis.
- Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD doses. Serious cardiovascular effects with overdose may precipitate sudden cardiac death. Prior to treating patients with dafabet online casino games, assess for the presence of cardiac disease. Avoid dafabet online casino games use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during dafabet online casino games treatment.
- CNS stimulants cause increase in blood pressure (mean increase about 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm). Monitor all dafabet online casino games for potential tachycardia and hypertension.
- Use of CNS stimulants may cause exacerbation of pre-existing psychosis and may induce maniac or mixed episode in patients with bipolar disorder. In patients without prior history of psychotic illness or mania, CNS stimulants may cause new psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) at the recommended dosage. Prior to initiating dafabet online casino games treatment, screen patients for risk factors for developing a manic episode. If new psychotic or manic symptoms occur, consider discontinuing dafabet online casino games.
- CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients with ADHD; monitor weight and height during treatment with dafabet online casino games. Treatment may need to be interrupted in children not growing as expected.
- CNS stimulants, including dafabet online casino games, are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for dafabet online casino games-treated patients who develop signs or symptoms of peripheral vasculopathy.
- Serotonin syndrome risk is increased when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), MAOIs, and during overdosage situations. If it occurs, discontinue dafabet online casino games and any concomitant serotonergic agents immediately, and initiate supportive treatment.
- CNS stimulants, including amphetamine, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette’s syndrome has also been reported. Before initiating dafabet online casino games, assess the family history and clinically evaluate patients for tics or Tourette’s syndrome. Regularly monitor dafabet online casino games-treated patients for the emergence or worsening of tics or Tourette’s syndrome and discontinue treatment if clinically appropriate.
- Most common adverse reactions observed with amphetamine products: dry mouth, anorexia, weight loss, abdominal pain, nausea, insomnia, restlessness, emotional lability, dizziness, and tachycardia. Based on limited experience with dafabet online casino games in controlled trials, the adverse reaction profile of dafabet online casino games appears similar to other amphetamine extended-release products. The most common (≥2% in the dafabet online casino games group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 108 patients with ADHD (aged 6 to 12 years) were: epistaxis (dafabet online casino games 4%, placebo 0%), allergic rhinitis (4%, 0%) and upper abdominal pain (4%, 2%).
- dafabet online casino games use during pregnancy may cause fetal harm. To monitor pregnancy outcomes in women exposed to dafabet online casino games during pregnancy, healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/.
- Because of the potential for serious adverse reactions in a breastfed infant, breastfeeding is not recommended during treatment with dafabet online casino games.
To report SUSPECTED ADVERSE REACTIONS, contact dafabet online casino games, Inc. at 1-732-940-0358 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see Full Prescribing Information, including Boxed Warning regarding ABUSE, MISUSE, AND ADDICTION.
dafabet online casino games® and Liquidafabet online casino games® are registered trademarks of dafabet online casino games, Inc.
Company Contact
Cheryl Patnick
dafabet online casino games, Inc.
cpatnick@trispharma.com
Media Contact
Laura Morgan
Sam Brown, Inc.
951.333.9110
lauramorgan@sambrown.com